PRESSENSA®

Quality Dermal Solutions

PUBLIC TECHNICAL DATASHEET

SKU: PRS-3194 | v1.0.0 | EN

Etternity Dermal S.L. | Madrid, Spain

SupremEffects

Line: Retail Skincare · Home Care | Presentation: Dermocosmetic daily home care format

Revitalizing, nourishing, moisturizing overnight cream. Facial Botox-like effect without invasive procedures. Revitalizing treatment of mature skin. It alleviates signs of fatigue by providing strength, flexibility and radiance to the skin, acts by...



KEY ACTIVE INGREDIENTS

- ARGIRELOX(TM) PEPTIDE - Maintains and extends the wrinkle reduction. Combats the wrinkles by modulating muscle contraction in the pre-synaptic pathway and is particularly directed to topical formulations claiming supplement injections of botulinum toxin type A for improving the results of anti-ageing
- LMW HYALURONIC ACID - For night deep hydration
- VITAMIN E - Nominated as eternal youth
- ARGIRELOX(TM) PEPTIDE - Maintains and extends the wrinkle reduction. Combats the wrinkles by modulating muscle contraction in the pre-synaptic pathway and is particularly directed to topical formulations claiming supplement injections of botulinum toxin type A for improving the results of anti-ageing

COSMETIC / CLINICAL INDICATIONS

- SupremEffects
- Revitalizing, nourishing, moisturizing overnight cream. Facial Botox-like effect without invasive procedures. Revitalizing treatment of mature skin. It alleviates signs of fatigue by providing strength, flexibility and radiance to the skin, acts by combating skin ageing giving it elasticity and softness. It helps the skin to rebuild a hydrolipidic film avoiding skin dryness.
- UBIQUINONE (COENZYME Q10) - Fights expression lines and cutaneous oxidation
- ROSEHIP EXTRACT - Multivitamin deeply nourishes and regenerates the small wrinkles

REGULATORY & QUALITY GOVERNANCE

Status: APPROVED (2026-11-26) | Reviewer: Etternity Dermal, S.L. · Technical Direction
Regulatory Classification: Cosmetic - Reg. (EC) 1223/2009 | Audience: Daily Home Care
Claims / Regulatory Standard: Regulation (EC) No 1223/2009 · Regulation (EU) No 655/2013 | Markets: EU, MENA, LATAM, CIS
RESTRICTED DOCUMENTATION NOTICE: Full clinical injection/needling protocols, SDS and regulatory dossiers are excluded from public builds and provided strictly via controlled access.